Skip to content. | Skip to navigation

Personal tools

You are here: Home / Teams / Regulation of Genome Architecture and Dynamics of Splicing (ReGArDS) - D. Auboeuf and C. Bourgeois / Publications / How mRNA is misspliced in acute myelogenous leukemia (AML)?

How mRNA is misspliced in acute myelogenous leukemia (AML)?

Aminetou M Mohamed, Morgan Thenoz, Francoise Solly, Marie Balsat, Franck Mortreux, and Eric Wattel (2014)

Oncotarget, 5(20):9534-45.

Approximately one-third of expressed genes are misspliced in AML, opening the possibility that additional factors than splicing factor mutations might cause RNA missplicing in these diseases. AML cells harbor a constellation of epigenetic modifications and regularly express large amounts of WT1 transcripts. Histone acetylation/methylation and DNA CpG methylation favor either exon skipping or inclusion, mainly through interfering with RNA Pol II-mediated elongation. This can result either from the binding of various factors on Pol II or alternativelyfrom the recruitment of DNA binding factors that create roadblocks to Pol II-induced elongation. WT1 exhibits pleiotropic effects on mRNA splicing, which mainly result from the binding properties of WT1 via its zinc fingers domains toDNA, RNA, and proteins. Through the repression of the kinase SRPK1, WT1 modifiesthe splicing of VEGF, which plays important roles in hematopoiesis and angiogenesis. At the protein level, WT1 interacts with the splicing factors U2AF2, WTAP, and RPM4. Therefore, AML cells appear to have acquired numerous properties known to interfere with mRNA splicing. The challenge is now to elucidate these links in order to trigger mRNA splicing at the therapeutic level.

automatic medline import

Document Actions